Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
On Tuesday, Pfizer announced its decision to donate the rights of royalties from sales of the cancer drug Bavencio to the American Association for Cancer Research. This move comes as a response to concerns raised by US antitrust regulators regarding Pfizer's proposed $43 billion acquisition of Seagen.
After receiving all necessary regulatory approvals, the deal is set to close on Thursday, nearly nine months since its initial announcement, as per Reuters.
Reorganization and Leadership Changes
Pfizer plans to establish a separate division dedicated to cancer drugs as part of its efforts to streamline operations. Additionally, the company intends to split its remaining commercial business into two divisions, one focused on the United States and the other on the rest of the world.
Chief Commercial Officer Angela Hwang will step down, allowing Aamir Malik to assume the US unit's commercial chief role. In the international unit, Alexandre de Germay will take on the position of commercial chief.
Sales and Financial Outlook
Bavencio, a vital cancer drug, generated sales amounting to $271 million for Pfizer in 2022. This acquisition of Seagen, with its targeted cancer therapies, comes at a crucial time for Pfizer. Facing the anticipated decline in COVID-related sales and the looming threat of generic competition for its top-selling drugs, Pfizer seeks to bolster its oncology portfolio and maintain its position as a leader in the pharmaceutical industry.
However, the acquisition faced scrutiny from the US Federal Trade Commission (FTC) earlier this year. In July, the FTC requested more information on the deal from both parties involved, seeking to ensure compliance with antitrust laws. Despite this additional hurdle, Pfizer remains committed to moving forward with the acquisition and closing the deal as planned.
Business Times noted that Seagen, based in Washington, is recognized as a pioneer of antibody-drug conjugates. These innovative treatments function like "guided missiles," specifically designed to target and destroy cancer cells while sparing healthy cells. With this cutting-edge technology and expertise, Seagen contributes to advancing more effective and targeted cancer therapies.
Photo: Pfizer Newsroom
